Results 71 to 80 of about 15,126 (225)

Can the gut-brain axis provide insight into psilocybin's therapeutic value in reducing stress?

Neurobiology of Stress
There is growing interest in exploring the therapeutic potential and mechanisms of action of psilocybin on stress-related neuropsychiatric disorders, including depression, generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD ...
Alanna Kit, Kate Conway, Savannah Makarowski, Grace O'Regan, Josh Allen, Sandy R. Shultz, Tamara S. Bodnar, Brian R. Christie   +7 more
doaj   +1 more source

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention

NeuroImage, 2020
Psychedelic drugs, including the serotonin 2a (5-HT2A) receptor partial agonist psilocybin, are receiving renewed attention for their possible efficacy in treating a variety of neuropsychiatric disorders.
Frederick S. Barrett, Samuel R. Krimmel, Roland R. Griffiths, David A. Seminowicz, Brian N. Mathur   +4 more
doaj   +1 more source

Insights into the pathogenesis of nicotine addiction. Could a salivary biosensor be useful in Nicotine Replacement Therapy (NRT)? [PDF]

, 2019
Nicotine has gained the attention of the medical community due to its insidious addictive mechanisms which lead to chronic consumption. The multitude of compounds derived from tobacco smoke have local and systemic negative impacts, resulting in a large ...
Alexescu, Teodora G, Bordea, Roxana, Boșca, Bianca A, Băbțan, Anida-Maria, Câmpian, Radu S, Feurdean, Claudia N, Ilea, Aranka, Ionel, Anca, Miclăuș, Viorel, Mirică, Codruța I, Petrescu, Nausica B, Ruxanda, Flavia, Todea, Adina D, Uriciuc, Willi A   +13 more
core   +2 more sources

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin [PDF]

, 2016
Emotional face processing is critically modulated by the serotonergic system. For instance, emotional face processing is impaired by acute psilocybin administration, a serotonin (5-HT) 1A and 2A receptor agonist.
Bernasconi, Fosco, Kometer, Michael, Pokorny, Thomas, Schmidt, André, Seifritz, Erich, Vollenweider, Franz X.   +5 more
core   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Psilocybin increases optimistic engagement over time: computational modelling of behaviour in rats

Translational Psychiatry
Psilocybin has shown promise as a novel pharmacological intervention for treatment of depression, where post-acute effects of psilocybin treatment have been associated with increased positive mood and decreased pessimism.
Elizabeth L. Fisher, Ryan Smith, Kyna Conn, Andrew W. Corcoran, Laura K. Milton, Jakob Hohwy, Claire J. Foldi   +6 more
doaj   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Optimized psilocybin production in tryptophan catabolism‐repressed fungi

Microbial Biotechnology
The high therapeutic potential of psilocybin, a prodrug of the psychotropic psilocin, holds great promise for the treatment of mental disorders such as therapy‐refractory depression, alcohol use disorder and anorexia nervosa.
Slavica Janevska, Sophie Weiser, Ying Huang, Jun Lin, Sandra Hoefgen, Katarina Jojić, Amelia E. Barber, Tim Schäfer, Janis Fricke, Dirk Hoffmeister, Lars Regestein, Vito Valiante, Johann E. Kufs   +12 more
doaj   +1 more source